|
| |
| | | | 1 | | | DO1.PCCNTR.2191941 ContractData Container |
| | | 1.1 | | | | | | | | | | 1,241,290.00 | 0.00 | 59,940.00 | 0.00 | 1,241,290.00 | 1,301,230.00 |
|
| | | | | | | 4 | | 42281703 - Kits de cuidad(...)42281703 - Kits de cuidado de instrumentos |
| 2.3.9.3.01 | KIT DE LAPARATOMIA | 100 | UD | 2,950 | 2,950 | 295,000.00 | | 0.00 | | 18 | 53,100.00 | | 0.00 | 295,000.00 | 348,100.00 | |
|
| | | | | | | 5 | | 42281803 - Kits biológico(...)42281803 - Kits biológicos de esterilización |
| 2.3.9.3.01 | BIOLENE 20 CC | 200 | UD | 1,975 | 1,975 | 395,000.00 | | 0.00 | | | 0.00 | | 0.00 | 395,000.00 | 395,000.00 | |
|
| | | | | | | 6 | | 42311604 - Hemostáticos d(...)42311604 - Hemostáticos de colágeno micro fibrilar |
| 2.3.9.3.01 | HEMOSTATICO SURGICEL ABSORBIBLE | 10 | UD | 4,480 | 4,480 | 44,800.00 | | 0.00 | | | 0.00 | | 0.00 | 44,800.00 | 44,800.00 | |
|
| | | | | | | 7 | | 42221501 - Catéteres de l(...)42221501 - Catéteres de línea arterial |
| 2.3.9.3.01 | TUBO ENDOTRAQUEAL CON BALON #4.5 | 200 | UD | 190 | 190 | 38,000.00 | | 0.00 | | 18 | 6,840.00 | | 0.00 | 38,000.00 | 44,840.00 | |
|
| | | | | | | 8 | | 2.3.4.1.01 | BUPIVACAINA SIPLE 0.5 % 20 ML | 498 | UD | 255 | 255 | 126,990.00 | | 0.00 | | | 0.00 | | 0.00 | 126,990.00 | 126,990.00 | |
|
| | | | | | | 9 | | 51172102 - Clorhidrato de(...)51172102 - Clorhidrato de dicicloverina |
| 2.3.4.1.01 | DYCINONE AMPOLLAS | 100 | UD | 405 | 405 | 40,500.00 | | 0.00 | | | 0.00 | | 0.00 | 40,500.00 | 40,500.00 | |
|
| | | | | | | 10 | | 51181707 - Metilprednisol(...)51181707 - Metilprednisolona |
| 2.3.4.1.01 | METILPREDNISOLONA 500 MG AMPOLLAS | 200 | UD | 1,100 | 1,100 | 220,000.00 | | 0.00 | | | 0.00 | | 0.00 | 220,000.00 | 220,000.00 | |
|
| | | | | | | 11 | | 2.3.4.1.01 | ASTREONAM 1 MG AMPOLLAS | 4 | UD | 12,600 | 12,600 | 50,400.00 | | 0.00 | | | 0.00 | | 0.00 | 50,400.00 | 50,400.00 | |
|
| | | | | | | 12 | | 2.3.4.1.01 | CEFTAZIDIMA 1 GM AMPOLLA | 60 | UD | 510 | 510 | 30,600.00 | | 0.00 | | | 0.00 | | 0.00 | 30,600.00 | 30,600.00 | |
|
|
| | | |
| | | |
|